Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

NCT01035502 is registered in ClinicalTrials.gov with Clavis Pharma as lead sponsor.

NCT NCT01035502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01035502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Lead sponsor
Clavis Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
June 30, 2013
Enrollment
51 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia